Life Healthcare Reports Strong H2-2024 Performance and Robust International Sales
Life Healthcare delivered a strong performance in the second half of 2024, particularly in its acute and complementary healthcare businesses in southern Africa. Acute hospital patient volumes showed positive growth, with paid patient days (PPDs) increasing by 1.6%. Occupancy rates…
Sickday Medical House Calls: Top Provider of On-Demand Care for NYC Travelers
Sickday Medical House Calls, the largest and longest-serving medical house call practice in New York City, is reshaping the way travelers experience healthcare. For nearly two decades, Sickday has been providing on-demand, high-quality medical care to visitors in the city,…
RadNet’s DeepHealth Expands FDA Clearance for SmartMammo™
DeepHealth, Inc., a subsidiary of RadNet, Inc. (NASDAQ: RDNT), has received expanded FDA 510(k) clearance for its groundbreaking mammography software, SmartMammo™. The enhanced clearance, announced recently, allows SmartMammo Dx, an AI algorithm, to be compatible with GE HealthCare’s Senographe Pristina™…
Teladoc Health Launches AI Motion Detection for Hospital Bed Safety
Teladoc Health has introduced a groundbreaking technology that combines artificial intelligence (AI) and real-time monitoring to enhance patient safety in hospitals. This innovative solution, known as Virtual Sitter, is designed to help hospital staff detect when a patient is at…
‘It’s Not Over’: AHF UK Commemorates World AIDS Day
In observance of World AIDS Day (WAD) 2024 on December 1, AHF UK will host a commemorative event on Monday, December 2, 2024, from 9:30 a.m. to 3:00 p.m. at Croydon University Hospital (530 London Road, Thornton Heath, Surrey, CR7…
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global leader in precision genetic medicine for rare diseases, announced on November 29, 2024, the granting of equity awards to 14 new employees who joined the company in November 2024. These equity awards, which…
Cigna Group Foundation Announces First Health Equity Impact Fund Grantees
The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), has announced its first round of grant recipients for The Cigna Group Health Equity Impact Fund. This initiative will distribute $9 million over the next three years…
FDA Approves AOP Health’s Rapiblyk™ (Landiolol) for Atrial Fibrillation and Flutter in Critical Care
AOP Orphan Pharmaceuticals GmbH (AOP Health), based in Vienna, Austria, has announced that the U.S. Food and Drug Administration (FDA) has approved Rapiblyk™ (landiolol) for the treatment of supraventricular tachycardia (SVT), including atrial fibrillation and atrial flutter, in critical care…
Galderma’s Phase III OLYMPIA 1 Data Shows Nemolizumab Improves Prurigo Nodularis Symptoms
Galderma recently announced that the full results from the Phase III OLYMPIA 1 trial, which evaluated the efficacy and safety of nemolizumab in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology. The data from this trial, in conjunction…
QIAGEN Expands QIAstat-Dx with New Barcelona Site to Boost Infectious Disease and Precision Medicine Growth
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today revealed plans to relocate its QIAstat-Dx operations to a new facility in Esplugues de Llobregat, near Barcelona. This move is part of a multi-year investment aimed at expanding and strengthening the company’s…
Hippocratic AI Granted US Patent for Key Innovation in Healthcare LLM Safety
Hippocratic AI, the company pioneering the first safety-focused Large Language Model (LLM) for healthcare, has announced the issuance of its first patent, US Patent 12,142,371, granted by the US Patent Office this month. This patent covers key innovations integrated into…
EU Approves BeiGene’s TEVIMBRA for Advanced Esophageal and Gastric Cancers
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company set to rebrand as BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell…